Taiwan Liposome Company, Ltd. - ADRs (TLC): Price and Financial Metrics
GET POWR RATINGS... FREE!
TLC POWR Grades
- TLC scores best on the Growth dimension, with a Growth rank ahead of 0% of US stocks.
- TLC's strongest trending metric is Sentiment; it's been moving down over the last 117 days.
- TLC ranks lowest in Growth; there it ranks in the 0th percentile.
TLC Stock Summary
- TLC's went public 2.55 years ago, making it older than only 5.94% of listed US stocks we're tracking.
- With a price/sales ratio of 69.41, Taiwan Liposome Company Ltd has a higher such ratio than 95.68% of stocks in our set.
- Taiwan Liposome Company Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -322.78%, greater than the shareholder yield of only 0.89% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Taiwan Liposome Company Ltd are YRD, SINO, TTNP, SONM, and SLRX.
- TLC's SEC filings can be seen here. And to visit Taiwan Liposome Company Ltd's official web site, go to www.tlcbio.com.
TLC Stock Price Chart Interactive Chart >
TLC Price/Volume Stats
|Current price||$5.99||52-week high||$12.65|
|Prev. close||$5.81||52-week low||$4.07|
|Day high||$6.06||Avg. volume||196,526|
|50-day MA||$5.63||Dividend yield||N/A|
|200-day MA||$5.03||Market Cap||252.04M|
Taiwan Liposome Company, Ltd. - ADRs (TLC) Company Bio
Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.
TLC Latest News Stream
|Loading, please wait...|
TLC Latest Social Stream
View Full TLC Social Stream
Latest TLC News From Around the Web
Below are the latest news stories about Taiwan Liposome Company Ltd that investors may wish to consider to help them evaluate TLC as an investment opportunity.
Taiwan Liposome (TLC) and Zydus Healthcare have signed a license supply and commercialization agreement for AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.AmphoTLC is indicated for severe systemic fungal infections such as mucormycosis. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC™ on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC™ in India. AmphoTLC™ is the first and on...
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC ) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute … Full story available on Benzinga.com
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India) for immediate importation per approved usage and indication, to aid in the country’s emergency of acute liposomal amphotericin B shortage. “AmphoTLC™ is the first and only complex generic drug to have achieved bioequivalence to Gilead’s AmBisome, proving its sameness to the safest form of amphotericin B in the world,” commented Geor...
TLC Price Returns
Continue Researching TLCWant to see what other sources are saying about Taiwan Liposome Company Ltd's financials and stock price? Try the links below:
Taiwan Liposome Company Ltd (TLC) Stock Price | Nasdaq
Taiwan Liposome Company Ltd (TLC) Stock Quote, History and News - Yahoo Finance
Taiwan Liposome Company Ltd (TLC) Stock Price and Basic Information | MarketWatch